metopirone 250 mg kapsel, mjuk
hra pharma rare diseases - metyrapon - kapsel, mjuk - 250 mg - propylenglykol hjälpämne; natriumpropylparahydroxibensoat hjälpämne; natriumetylparahydroxibensoat hjälpämne; glycerol 85% hjälpämne; metyrapon 250 mg aktiv substans - metyrapon
ingelvac mycoflex injektionsvätska, suspension
boehringer ingelheim vetmedica gmbh - mycoplasma hyopneumoniae, stam j, inaktiverad - injektionsvätska, suspension - karbomer 1 mg adjuvans; mycoplasma hyopneumoniae, stam j, inaktiverad 1 - 4,61 rp aktiv substans - mykoplasmavaccin - svin
ingelvac mycoflex injektionsvätska, suspension
2care4 aps - mycoplasma hyopneumoniae, stam j, inaktiverad - injektionsvätska, suspension - karbomer 1 mg adjuvans; mycoplasma hyopneumoniae, stam j, inaktiverad 1 - 4,61 rp aktiv substans - mykoplasmavaccin - svin
mycophenolate mofetil teva
teva pharma b.v. - mykofenolatmofetil - graftförkastning - immunsuppressiva - mycophenolate mofetil teva är indicerat i kombination med ciklosporin och kortikosteroider för profylax av akut transplantatavstötning hos patienter som får allogen njur-, hjärt- eller leverfunktion transplantationer.
circomax myco
zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiska medel för suidae - grisar (för gödning) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.
ms-h vaccine
pharmsure veterinary products europe ltd - mycoplasma synoviae-stam ms-h - immunologicals för aves, live bakteriella vacciner - kyckling - för aktiv immunisering av framtida könsuppfödarehönor, framtida lageruppfödarehönor och framtida lagerhönor för att minska sårskador och minska antalet ägg med onormal skalbildning orsakad av mycoplasma synoviae.
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - grisar - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
bcg-medac pulver och vätska till intravesikal suspension
medac gesellschaft für klinische spezialpräparate mbh - mycobacterium bovis, bacillus calmette-guérin (bcg), rivm-deriverad stam (1173-p2), levande försvagad - pulver och vätska till intravesikal suspension - mycobacterium bovis, bacillus calmette-guérin (bcg), rivm-deriverad stam (1173-p2), levande försvagad 8,3 - 9,48 log10 cfu aktiv substans; glukos (vattenfri) hjälpämne - vaccin mot bacillus calmette-guerin (bcg)
bcg-vaccin ajvaccines pulver och vätska till injektionsvätska, suspension
aj vaccines a/s - mycobacterium bovis, bacillus calmette-guérin (bcg), stam 1331, levande försvagad - pulver och vätska till injektionsvätska, suspension - mycobacterium bovis, bacillus calmette-guérin (bcg), stam 1331, levande försvagad 6,3 - 6,9 log10 cfu aktiv substans; glycerol 85% hjälpämne - levande försvagat
oncotice 12,5 mg pulver till lösning för intravesikal användning
merck sharp & dohme bv - mycobacterium bovis, bacillus calmette-guérin (bcg), stam tice, levande försvagad - pulver till lösning för intravesikal användning - 12,5 mg - mycobacterium bovis, bacillus calmette-guérin (bcg), stam tice, levande försvagad 12,5 mg aktiv substans; glycerol hjälpämne; laktosmonohydrat hjälpämne - vaccin mot bacillus calmette-guerin (bcg)